Aquestive Therapeutics Stock (NASDAQ: AQST)

Aquestive Therapeutics

AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Professional,Doctor.,Smart,Nice,Otolaryngologist,Sitting,In,Front,Of,The

Biotech

News

Health Care

General

AQST

Aquestive&#39;s Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025.

Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data

Auto,Epinephrine,Injector.,Patient,Doing,Leg,Injection

Analyst Color

Equities

Price Target

Initiation

Analyst Ratings

Trading Ideas

Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm&#39;s potential to disrupt the epinephrine auto-injector market with 200% upside.

Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Movers

INCY

Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC Wainwright raises its price target amid promising developments.

Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

Press Releases

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Earnings

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

ALT5 Sigma

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

scPharmaceuticals

Septerna

SNDL

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tvardi Therapeutics

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Aquestive Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell